ArticleCell death & disease2025
Tumor exosomal circPTBP3 drives gastric cancer peritoneal metastasis via mesothelial-mesenchymal transition.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Extracellular vesicles in gastric cancer: biological functions, clinical applications, and engineering strategies.Medical oncology (Northwood, London, England) · 2026Review
- Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM.Journal of gastrointestinal oncology · 2026Article
- Liquid Biopsy for Molecular Residual Disease Detection and Postoperative Surveillance in Gastric Cancer: Current Evidence and Future Directions.International journal of molecular sciences · 2026Review
- Gastric cancer-secreted galectin-1 promotes peritoneal mesothelial-mesenchymal transition to prime peritoneal metastasis soil.iScience · 2026Article
- Tumor-Derived Exosomal TAGLN2 Promotes Metastasis by Inducing Vascular Permeability and Angiogenesis via the NRP1/SEMA4D/YAP Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Integrated microbial and transcriptomic profiling reveals distinct correlations in atrophic gastritis associated with liver cirrhosis.Frontiers in cellular and infection microbiology · 2026Article
- Exosome-mediated metabolic-immune regulatory axis: mechanisms of gastric cancer progression and resistance and targeting strategies.Frontiers in immunology · 2026Review
- Exosome-orchestrated network in gastric cancer: mechanisms, immune regulation, biomarkers and therapeutic vehicles.Frontiers in cell and developmental biology · 2026Review
- Targeting the remodeled peritoneal ecosystem: a paradigm shift from tumor cells to the microenvironment in gastric cancer peritoneal metastasis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The peritoneum is the most common site of metastasis in advanced gastric cancer (GC), and the mechanisms underlying this process of gastric cancer peritoneal metastasis (GCPM) remain largely elusive. Mesothelial-mesenchymal transition (MMT) plays a crucial role in the progression of GCPM. In our current study, the data confirmed that GC-derived exosomes could significantly promote peritoneal metastasis through an MMT-dependent manner in vivo and in vitro. Using RNA-seq, we successfully identified a key circular RNA (circPTBP3). The expression of exosomal circPTBP3 in the plasma of GCPM patients was significantly upregulated and closely correlated with tumor differentiation, depth of invasion, lymphatic invasion, peritoneal metastasis, and TNM stage. Exosomal circPTBP3 thus serves as a reliable diagnostic and prognostic indicator in GCPM patients. Mechanistically, exosomal circPTBP3 could effectively promote the MMT phenotype of mesothelial cells in vitro. Located in the nucleus, circPTPB3 was found to recruit transcription factor AP-2-beta (TFAP2B) to the serum- and glucocorticoid-inducible kinase 1 (SGK1) promoter sites, thereby initiating its transcription in mesothelial cells. These findings suggest that exosomal circPTPB3 functions as a pivotal mediator in facilitating the interplay between GC cells and mesothelial cells, and it provides a promising diagnostic indicator and therapeutic target for GCPM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.